ABOUT
OUR COMPANY
Management Team
Onconova Therapeutics is advised by a group of thought leaders with significant expertise in targeted cancer therapeutics, clinical development, and commercialization.
Steven M. Fruchtman, M.D.
President & CEO
Dr. Fruchtman joined Onconova in January 2015 as Chief Medical Officer. He was promoted to President in July 2018 and to President & CEO in January 2019. He has extensive experience in large and small biopharmaceutical companies and has led successful clinical development programs while serving in senior positions at Ortho Biotech Products, Novartis, Allos Therapeutics, Spectrum Pharmaceuticals and Syndax Pharmaceuticals.
Previously, Dr. Fruchtman was on the faculty of the Mount Sinai School of Medicine and the Director of the Stem Cell Transplantation and Myeloproliferative Disorder Programs at Mount Sinai Hospital in New York City. He is an author of more than 170 lectures, presentations, books, chapters, and abstracts and serves as an external reviewer for multiple medical journals.
Dr. Fruchtman received his medical degree from New York Medical College with the distinction of membership in the Alpha Omega Alpha honorary medical fraternity.
Mark Guerin
Chief Financial Officer
Mr. Guerin joined Onconova Therapeutics in September 2013 to augment the financial reporting, forecasting, and internal controls capabilities of the company following the IPO in July 2013. Prior to joining Onconova, Mr. Guerin worked as an interim senior finance & accounting executive facilitating the post-acquisition integration activities of newly-acquired private equity portfolio companies.
Previously, Mr. Guerin was the VP Finance & CFO of Cardiokine, Inc. through that company’s filing of a New Drug Application and the sale of the company. Prior to joining Cardiokine, Mr. Guerin was Director, Financial Reporting & Internal Controls at Barrier Therapeutics, Inc. during Barrier’s IPO and follow-on offering. Mr. Guerin started his career at Coopers & Lybrand in Philadelphia. He received his bachelor’s degree in Accounting from DeSales University and has earned the CPA, CMA, and CFM professional certifications.
Ric Woodman, M.D.
Chief Medical Officer and Senior Vice President,
Research & Development
Richard “Ric” Woodman, M.D., joined Onconova as Chief Medical Officer in November 2018. Prior to joining Onconova, Dr. Woodman served as Senior Vice President and Head of U.S. Clinical Development and Medical Affairs (USCDMA) which is responsible for all phase IB-IV oncology/hematology clinical programs. Ric provided strategic medical and scientific leadership for both marketed and development-stage compounds.
Previously, Ric served as Franchise Head for Hematology in Global Medical Affairs at Novartis Oncology. His responsibilities included global oversight of non-registration clinical programs and studies for Tasigna(r), Glivec(r), Odomzo(r), Panobinostat(r), Midostaurin(r) and CTL019. Before joining Novartis Oncology, Dr. Woodman was Senior Medical Director with Johnson & Johnson leading the Oncology franchise at Ortho Biotech Products, LP, where he supervised both investigator- and company-sponsored oncology and hematology studies for Procrit(r) in the U.S.
Dr. Woodman joined the faculty of the University of Calgary in Canada in 1990 and held appointments as Professor in the Departments of Medicine and Oncology and was a full member in the Immunology Research Group. He served as Acting Head for the Division of Hematology and Hematological Malignancies for the University of Calgary and Calgary Health Region, and acted as a consultant in adult and pediatric hematology at the Alberta Children’s Hospital, Tom Baker Cancer Center, Foothills Medical Center, and Calgary Laboratory Services.
Dr. Woodman completed a postdoctoral research fellowship at Scripps Clinic and Research Institute in the Department of Experimental Medicine, and has authored more than 90 peer-reviewed publications in the areas of hematology and immunology. He received his medical degree from the University of Calgary in June 1981.
Manoj Maniar, Ph.D.
Senior Vice President, Product Development
Dr. Maniar received his B.S. in Pharmacy from Bombay College of Pharmacy and his Ph.D. in Pharmaceutics from the University of Connecticut. He has led the development and commercialization of several pharmaceutical products and medical devices during his career. Prior to joining Onconova, Dr. Maniar was with SRI International, where he served as Senior Director, Formulations and Drug Delivery. He has authored more than 100 patents, publications, and presentations in the field of pharmaceutical sciences.
Avi Oler
Senior Vice President, Corporate Development & General Counsel
Mr. Avi Oler joined Onconova’s Management Team in December 2018 as Vice President, Corporate Development and General Counsel and was promoted to Senior Vice President, Corporate Development & General Counsel in January of 2020. Mr. Oler is primarily responsible for business development, investor relations, and legal affairs of the Company.
Mr. Oler served most recently as Vice President of Operations and Chief of Staff to the CEO of Spectrum Pharmaceuticals. During his tenure, he was instrumental in the company’s progress and productive licensing activities. He served in varied roles of increasing responsibility, as a member of the executive management team, the corporate development team, and as Head of Alliances and Legal Affairs. Due to a series of successful accomplishments, he was named Chief of Staff.
Previously, Mr. Oler practiced corporate law at the law firm of Kirkland & Ellis LLP. Prior to this, he was a financial research analyst at the Center for Financial Research & Analysis, and an investment banker with Lehman Brothers in London.
Mr. Oler holds a JD from Northwestern University School of Law with Distinction, an MBA from Kellogg School of Management with Distinction, and a Master of Science in Politics of the World Economy from the London School of Economics. He earned his undergraduate degrees, magna cum laude, from the Wharton School and the University of Pennsylvania.
Scientific Advisory Board
Onconova Therapeutics is advised by a group of thought leaders with significant expertise in targeted cancer therapeutics, clinical development, and commercialization.
Alan R. Williamson, Ph.D.
Chairman
Dr. Williamson has extensive experience in pharmaceutical discovery. He served as Vice President of Basic Research and Vice President, Research Strategy Worldwide, for Merck. Previously he was with Glaxo, UCLA, University of Glasgow, and the National Institute for Medical Research, U.K. He is the recipient of the Colworth Medal of the Biochemical Society and a member of the EMBL. He was elected Fellow of the Royal Society of Edinburgh in 1976 and Fellow of the Institute of Biology in 1982. Dr. Williamson sits on the scientific advisory board of Illumina. He is a consultant to the venture capital firm Abingworth Management Ltd.
David R. Parkinson, M.D.
Venture Partner at NEA
Dr. Parkinson is a Venture Partner at New Enterprise Associates (NEA). From 2007 to 2012, Dr. Parkinson served as President and CEO of Nodality Inc., a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and decision-making. Previously, Dr. Parkinson was Senior Vice President, Oncology Research and Development at Biogen Idec. At Biogen he oversaw all oncology discovery research efforts and the development of the oncology pipeline. Previously he had served as Vice President, Oncology Development, at Amgen and Vice President, Global Clinical Oncology Development at Novartis. During his tenures at Amgen and Novartis Dr. Parkinson was responsible for clinical development activities leading to a series of successful global drug registrations for important cancer therapeutics, including Gleevec®, Femara®, Zometa®, Kepivance®, and Vectibix®. Dr. Parkinson worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as Acting Associate Director of the Cancer Therapy Evaluation Program, before leaving for Novartis. He has also held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine. He received his M.D. as gold medalist from the University Of Toronto Faculty Of Medicine in 1977, with Internal Medicine and Hematology/Oncology training in Montreal at McGill University and in Boston at New England Medical Center. Dr. Parkinson is a past Chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA’s Cody Medal. He is a past President of the International Society of Biological Therapy, and past Editor of the Journal of Immunotherapy. He currently serves on the National Cancer Policy Forum of the Institute of Medicine and is a member of the FDA’s Science Board. He was recently elected to the Board of Directors of the American Association of Cancer Research, and he continues to serve as Chairman of the AACR Finance Committee.
George F. Vande Woude, Ph.D.
Van Andel Research Institute
Dr. Vande Woude served as research virologist for the US Department of Agriculture at Plum Island Animal Disease Center prior to his career at the National Cancer Institute (NCI) where he served successively as Head of the Human Tumor Studies and Virus Tumor Biochemistry Sections, Chief of the Laboratory of Molecular Oncology, and Director of the Advanced Bioscience Laboratories-Basic Research Program. He was Special Advisor to the Director of NCI and served to reorganize the intramural basic science at NCI. In 1999, he was selected to be the first Director of the newly created Van Andel Research Institute in Grand Rapids, Michigan. Dr. Vande Woude is the recipient of many awards honoring his contributions, is author of over 250 scientific research articles and over 60 articles in books or monographs, and is a member of the National Academy of Sciences.
Ross C. Donehower, M.D.
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Dr. Donehower is Professor of Oncology, the Director of Medical Oncology/Hematology Fellowship Training program and a Director in the Division of Medical Oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. His current clinical interests lie in gastrointestinal cancers and drug development. Dr. Donehower performed his postgraduate training in internal medicine at Johns Hopkins, and has worked at the U.S. Public Health Service and at the National Cancer Institute in Bethesda. He is currently director of both the Division of Medical Oncology in the Department of Oncology and of the Medical Oncology Fellowship Training Program at the Johns Hopkins Kimmel Comprehensive Cancer Center as well as a Professor of Oncology and Medicine. Dr. Donehower performed pioneering work in clinical studies of paclitaxel (Taxol®), one of the most important chemotherapy agents developed in the last several decades.
Stephen Nimer, M.D.
Sylvester Comprehensive Cancer Center at the University of Miami Hospitals and Clinics
Dr. Nimer is a Professor of Medicine, Biochemistry & Molecular Biology and Director at the Sylvester Comprehensive Cancer Center at the University of Miami Hospitals and Clinics. He received his medical degree from the University of Chicago Pritzker School of Medicine and completed his Internship and Residency in Internal Medicine at the University of California-Los Angeles (UCLA) School of Medicine, where he was named Chief Medical Resident. He remained at UCLA for his Fellowship in Hematology and Oncology. Dr. Nimer is a Fellow of the American College of Physicians and a member of the American Society for Clinical Investigation, the American Society of Hematology, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is on the editorial boards of several journals, such as Leukemia Research and the American Journal of Oncology Review. He is a reviewer for the New England Journal of Medicine, Blood, and Nature Medicine. Dr. Nimer has published over 120 research articles and given numerous presentations at scientific meetings.
Anna Marie Skalka, Ph.D.
Fox Chase Cancer Center
Dr. Skalka is Professor, W.W. Smith Chair in Cancer Research and Senior Advisor to the President at the Fox Chase Cancer Center in Philadelphia. She is a leading expert in the molecular biology of retroviruses and the molecular basis of cancer. In recognition of her outstanding accomplishments, Dr. Skalka has been elected as a Fellow to the American Academy of Microbiology, the American Association for the Advancement of Science, the American Academy of Arts and Science, and the New York Academy of Science.
